SCShan Chung

Shan Chung

*This is an algorithmically generated author record based on publicly available information.

Shan Chung has a total of 101 co-authors. Here are the top co-authors by number of shared publications:

  • An Song

    Department of BioAnalytical Sciences, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080-4990, United States; Immune-Onc Therapeutics, 4030 Fabian Way, Palo Alto, CA 94303, United States

    5 shared publications
  • Van Nguyen

    Department of Bioanalytical Science, Genentech, Inc., South San Francisco, USA

    5 shared publications
  • Kai Zheng

    Department of Late Stage Pharmaceutical Development, Genentech Inc, 1 DNA Way, South San Francisco, CA 94080-4990, United States

    4 shared publications
  • Srividya Myneni

    Department of BioAnalytical Sciences, Genentech Inc, South San Francisco, CA, USA

    4 shared publications
  • Jochen Brumm

    Early Development Biometrics, Genentech, Inc., South San Francisco, USA

    3 shared publications
  • Joyce Guerrero

    Department of BioAnalytical Sciences, Genentech Inc., South San Francisco, CA94080, USA

    3 shared publications

Latest Publications

  • Open Access

    Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier

    by Julien Lafrance-Vanasse, Shraddha S. Sadekar, Yanli Yang, Daniela Bumbaca Yadav, William J. Meilandt, Monica K. Wetzel-Smith, Hao Cai, Susan R. Crowell, Van Nguyen, Vivian Lee, et al.

    The blood-brain barrier (BBB) restricts efficient penetration of systemically delivered therapeutic antibodies into the brain, limiting the development of this class of drugs to treat neurodegenerative diseases. Here we demonstrate that the neonatal Fc receptor (FcRn), which is highly expressed at the BBB, can be used to facilitate IgG transport to the brain. Engineering of the antibody Fc region to promote binding to FcRn at neutral pH enhances antibody transcytosis in a cellular model. In vivo, these modifications improve brain penetration, as well as brain target engagement and activity, of systemically administered antibodies in both mice and non-human primates. This engineering approach can be broadly implemented to enhance central nervous system (CNS) exposure of antibody- and Fc-based drugs, improving the clinical potential of biotherapeutics for the treatment of human brain diseases.


  • Introducing Dendritic Cell Antibody Internalization as an Immunogenicity Risk Assessment Tool

    by Rachel Melendez, Benjamin Ordonia, Joyce Guerrero, Azadeh Hassanzadeh, Peter Tran, Justin Low, Manda Wong, Jochen Brumm, Shan Chung, Lynn Kamen

    Aim: Immunogenicity risk assessment assays are powerful tools that assess the relative immunogenicity of potential biotherapeutics. We detail here the development of a novel assay that measures the...


  • Methods for Functional Characterization of FcRn Interactions with Therapeutic Antibodies and Fc-Fusion Proteins

    by Shan Chung, Yuwen L. Lin, Van Nguyen, Chang Liu

    The neonatal Fc receptor (FcRn) plays a key role in determining the pharmacokinetic behavior of therapeutic monoclonal antibodies (mAbs). FcRn-mediated intracellular trafficking mechanisms extend the half-lives of mAbs by rescuing them from lysosomal degradation and contribute to their transportation from the vascular space to tissue compartments such as placenta and mucosal surfaces. It is important to characterize the FcRn interactions of therapeutic mAbs and Fc-fusion proteins due to its potential impact on their in vivo pharmacokinetic properties such as clearance and half-life. In this chapter, we describe protocols for two cell-based assays that measure the total function of FcRn which involves pH-dependent association and dissociation with IgG-Fc, as well as FcRn-mediated intracellular trafficking parameters. These assays are suitable for characterization of FcRn interactions with therapeutic mAbs and Fc-fusion proteins for the purpose of assessing lot-to-lot consistency and the structural and functional integrity of the Fc domain. In addition, they may serve as cost-effective screening tools for the evaluation of mAb-based drug candidates during lead selection and optimization for desired pharmacokinetic properties.


  • A Cell-Based FcRn-dependent Recycling assay for Predictive Pharmacokinetic assessment of Therapeutic Antibodies

    by Chang Liu, Yeon Su Kim, John Hok-Nin Lowe, Shan Chung

    Aim: Evaluation of suitable pharmacokinetic properties is critical for successful development of IgG-based biotherapeutics. The prolonged half-lives of IgGs depend on the intracellular trafficking ...


  • In Vitro Immunogenicity Prediction: Bridging between Innate and Adaptive Immunity

    by Sivan Cohen, Shan Chung

    Development of antidrug antibodies (ADAs) is an undesirable potential outcome of administration of biotherapeutics and involves the innate and adaptive immune systems. ADAs can have detrimental cli...


  • Open Access

    An integrated approach for characterizing immunogenic responses toward a bispecific antibody

    by Sivan Cohen, Shan Chung, Christoph Spiess, Victor Lundin, Eric Stefanich, Steven T. Laing, Vanessa Clark, Jochen Brumm, Ying Zhou, Catherine Huang, et al.

    Bispecific antibodies (bsAbs) recognize and bind two different targets or two epitopes of the same antigen, making them an attractive diagnostic and treatment modality. Compared to the production of conventional bivalent monospecific antibodies, bsAbs require greater engineering and manufacturing. Therefore, bsAbs are more likely to differ from endogenous immunoglobulins and contain new epitopes that can increase immunogenic risk. Anti-A/B is a bsAb designed using a ‘knobs-into-holes’ (KIH) format. Anti-A/B exhibited an unexpectedly high immunogenicity in both preclinical and clinical studies, resulting in early termination of clinical development. Here, we used an integrated approach that combined in silico analysis, in vitro assays, and an in vivo study in non-human primates to characterize anti-A/B immunogenicity. Our findings indicated that the immunogenicity is associated with epitopes in the anti-B arm and not with mutations engineered through the KIH process. Our results showed the value of this integrated approach for performing immunogenicity risk assessment during clinical candidate selection to effectively mitigate risks during bsAb development.


  • Open Access

    Immunogenicity risk assessment for biotherapeutics through in vitro detection of CD134 and CD137 on T helper cells

    by Sivan Cohen, Srividya Myneni, Anna Batt, Joyce Guerrero, Jochen Brumm, Shan Chung

    Biotherapeutics, which are biologic medications that are natural or bioengineered products of living cells, have revolutionized the treatment of many diseases. However, unwanted immune responses still present a major challenge to their widespread adoption. Many patients treated with biotherapeutics develop antigen-specific anti-drug antibodies (ADAs) that may reduce the efficacy of the therapy or cross-react with the endogenous counterpart of a protein therapeutic, or both. Here, we describe an in vitro method for assessing the immunogenic risk of a biotherapeutic. We found a correlation between clinical immunogenicity and the frequency with which a biotherapeutic stimulated an increase in CD134, CD137, or both cell surface markers on CD4+ T cells. Using high-throughput flow cytometry, we examined the effects of 14 biotherapeutics with diverse rates of clinical immunogenicity on peripheral blood mononuclear cells from 120 donors with diverse human leukocyte antigen class II-encoding alleles. Biotherapeutics with high rates of ADA development in the clinic had higher proportions of CD4+ T cells positive for CD134 or CD137 than biotherapeutics with low clinical immunogenicity. This method provides a rapid and simple preclinical test of the immunogenic potential of a new candidate biotherapeutic or biosimilar. Implementation of this approach during biotherapeutic research and development enables rapid elimination of candidates that are likely to cause ADA-related adverse events and detrimental consequences.


  • A novel method for determining antibody-dependent cellular phagocytosis

    by Lynn Kamen, Srividya Myneni, Chris Langsdorf, Elviza Kho, Benjamin Ordonia, Tara Thakurta, Kai Zheng, An Song, Shan Chung


  • Development of a kinetic antibody-dependent cellular cytotoxicity assay

    by Lynn Kamen, Tara Thakurta, Srividya Myneni, Kai Zheng, Shan Chung


  • Open Access

    Anin vitroFcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humans

    by Shan Chung, Van Nguyen, Yuwen Linda Lin, Julien Lafrance-Vanasse, Suzie J. Scales, Kevin Lin, Rong Deng, Kathi Williams, Gizette Sperinde, Juan Jenny Li, et al.

    A cell-based assay employing Madin–Darby canine kidney cells stably expressing human neonatal Fc receptor (FcRn) heavy chain and β2-microglobulin genes was developed to measure transcytosis of monoclonal antibodies (mAbs) under conditions relevant to the FcRn-mediated immunoglobulin G (IgG) salvage pathway. The FcRn-dependent transcytosis assay is modeled to reflect combined effects of nonspecific interactions between mAbs and cells, cellular uptake via pinocytosis, pH-dependent interactions with FcRn, and dynamics of intracellular trafficking and sorting mechanisms. Evaluation of 53 mAbs, including 30 marketed mAb drugs, revealed a notable correlation between the transcytosis readouts and clearance in humans. FcRn was required to promote efficient transcytosis of mAbs and contributed directly to the observed correlation. Furthermore, the transcytosis assay correctly predicted rank order of clearance of glycosylation and Fv charge variants of Fc-containing proteins. These results strongly support the utility of this assay as a cost-effective and animal-sparing screening tool for evaluation of mAb-based drug candidates during lead selection, optimization, and process development for desired pharmacokinetic properties.